Implementing good clinical practice in two noncommercial phase II studies in children with cancer

Onkologie

Volumn 30, Issue 1-2, 2007, Pages 21-26

  Wagner Bohn, A ^a   Ripkens Reinhard, A ^a   Benninger Doring G ^a   Boos, J ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Clinical trials, noncommercial; Good Clinical Practice; Pediatric oncology; Phase II studies

Indexed keywords

ARTICLE; CANCER RESEARCH; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL RESEARCH; DRUG RESEARCH; GOOD CLINICAL PRACTICE; PRACTICE GUIDELINE;

CHILD; CLINICAL TRIALS, PHASE II; DEOXYCYTIDINE; EUROPEAN UNION; FINANCING, GOVERNMENT; GERMANY; HUMANS; INFORMED CONSENT; MEDICAL ONCOLOGY; NEOPLASMS; PEDIATRICS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 33846603115     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098424     Document Type: Article

References (18)

1. Richtlinie 2001/20/EG des Europäischen Parlaments und des Rates vom 4. April 2001 zur Angleichung der Rechts- und Verwaltungsvorschriften der Mitgliedsstaaten über die Anwendung der guten klinischen Praxis bei der Durchführung von klinischen Prüfungen mit Humanarzneimitteln. Amtsblatt der Europäischen Gemeinschaften, L 121, 34-44.
2. ICH Topic E6, Guideline for Good Clinical Practice. CPMP/ICH/135/95, 1997.
3. Dreier G, Marx C, Schmoor C, Maier-Lenz H: The 12th amendment to the German Drug Law. Chances and obstacles for investigator-initiated clinical trials. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005;48:445-452.
4. Boos J: Quality requirements governing non-commercial clinical trials within the framework of clinical drug development in humans in the EU. Challenges, opportunities, and questions experienced by treatment centres. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005;48:196-203.
5. Wagner-Bohn A, Henze G, von Stackelberg A, Boos J: Phase II study of gemcitabine in children with relapsed leukemia. Pediatr Blood Cancer 2006;46:262.
6. Wagner-Bohn A, Paulussen M, Vieira Pinheiro JP, Gerss J, Stoffregen C, Boos J: Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin. Anticancer Drugs 2006;17:859-864.
7. Zwölftes Gesetz zur Änderung des Arzneimittelgesetzes vom 30. Juli 2004. Bundesgesetzblatt Jahrgang 2004 Teil I, Nr. 41, 2031-2053.
8. Angiolillo AL, Whitlock J, Chen Z, Krailo M, Reaman G: Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): a Children's Oncology Group Report. Pediatr Blood Cancer 2006;46:193-197.
9. Benninger-Döring G, Boos J: Non-commercial trials - who will be the legal sponsor? Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2006;49:675-680.
10. Baeyens AJ: Impact of the European Clinical Trials Directive on academic clinical research. Med Law 2004;23:103-110.
11. Verordnung über die Anwendung der guten klinischen Praxis bei der Durchführung von klinischen Prüfungen mit Arzneimitteln zur Anwendung am Menschen (GCP-Verordnung - GCP-V) vom 9. August 2004. Bundesgesetzblatt Jahrgang 2004 Teil I, Nr. 42, 2081-2091.
12. Rushforth H: Practitioner review: communicating with hospitalised children: review and application of research pertaining to children's understanding of health and illness. J Child Psychol Psychiatry 1999;40:683-691.
13. Berry SL, Hayford JR, Ross CK, Pachman LM, Lavigne JV: Conceptions of illness by children with juvenile rheumatoid arthritis: a cognitive developmental approach. J Pediatr Psychol 1993;18:83-97.
14. Creutzig U, Zimmermann M, Hannemann J, Kramer I, Pfistner B, Herold R, Henze G: Quality management for clinical trials within the German network. Onkologie 2005;28:333-336.
15. Jorgensen A, Bach KF, Friis K: Good clinical practice is now obligatory in academic clinical drug research in the European Union. Basic Clin Pharmacol Toxicol 2004;94:57-58.
16. Ohmann C, Albrecht J: Coordination centers for clinical studies-structure and integration of non-university hospitals. Kongressbd Dtsch Ges Chir Kongr 2001;118:804-808.
17. Grienenberger A: Establishing pan-European clinical trials: regulatory compliance and other practical considerations. J Biolaw Bus 2004;7:58-63.
18. Boos J: Clinical trials for children. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005;48:530-535.